Hester Biosciences has reported a turnover of Rs. 651.04 million as compared to Rs. 482.64 million for the year 2011-12, thereby registering a growth of 34.89%. PBT increased by 23.14% in the corresponding period.

The Board of Directors have recommend a dividend of 20%, that is Rs. 2.00 per equity share for the financial year 2012-13, subject to the approval from the shareholders. The Board has further proposed to formulate a dividend payout policy for the company which would be implemented from the financial year 2013-14.

During 2012-13 Hester was awarded WHO-GMP certification. It also made its foray into animal health products with a wide range of medicines and feed additives. Additionally a bivalent Marek's Disease live vaccine for the poultry was developed which will prove to be an import replacement. Also in addition to 5 cattle vaccines, a PPR vaccine (for sheep & goat) and Brucella vaccine (for cattle) were developed which would contribute towards the disease eradication programs of the Government of India